However, there is still a need to clarify the role of PI3K–Akt-activating mutations in melanoma after the inhibition of the MAPK pathway by focusing on the understanding of the interaction between the MAPK and PI3K–Akt pathways. This evidence concerns the gene PIK3CG and melanoma.